Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - Organogenesis (NASDAQ: ORGO) reported fourth quarter EPS of $0.040, $0.05 better than the analyst estimate of $-0.010. Revenue for the quarter came in at $126.66M versus the consensus estimate of $109.61M.
Guidance
Organogenesis sees FY 2025 revenue of $480.000M-$535.000M versus the analyst consensus of $472.900M.
Organogenesis’s stock price closed at $3.07. It is down -20.670% in the last 3 months and down -12.030% in the last 12 months.
Organogenesis saw 0 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Organogenesis’s stock price’s past reactions to earnings here.
According to InvestingPro, Organogenesis’s Financial Health score is "good performance".
Check out Organogenesis’s recent earnings performance, and Organogenesis’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar